EPISODE · Nov 22, 2024 · 3 MIN
Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients
from Hormone Insight
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.For summary, click here.Packer M, Zile MR, Kramer CM, et al. (2024). “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine. DOI: 10.1056/NEJMoa2410027
Embed this episode
Ready to play
Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients
No transcript for this episode yet
Similar Episodes
No similar episodes found.